INS and metabolic syndrome: Sixteen subjects out of the initially recruited 93 were ruled out from the study: 6 (38%) owing to medically treated dyslipidemia; 5 (31%) owing to medically treated hypertension; 3 (19%) owing to medically treated dysthyroidism; 1 (6%) owing to type I insulin-treated diabetes and 1 (6%) owing to type II oral hypoglycemizing treated diabetes.